Free Trial

Warby Parker (WRBY) Competitors

+0.07 (+0.43%)
(As of 06/14/2024 ET)


Should you be buying Warby Parker stock or one of its competitors? The main competitors of Warby Parker include Bausch + Lomb (BLCO), RxSight (RXST), STAAR Surgical (STAA), National Vision (EYE), Innovative Eyewear (LUCY), Alcon (ALC), Cooper Companies (COO), Blueprint Medicines (BPMC), Masimo (MASI), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.

Warby Parker vs.

Warby Parker (NYSE:WRBY) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Warby Parker and Bausch + Lomb both received 24 outperform votes by MarketBeat users. However, 38.71% of users gave Bausch + Lomb an outperform vote while only 32.88% of users gave Warby Parker an outperform vote.

Warby ParkerOutperform Votes
Underperform Votes
Bausch + LombOutperform Votes
Underperform Votes

Warby Parker currently has a consensus target price of $16.50, indicating a potential upside of 1.79%. Bausch + Lomb has a consensus target price of $19.45, indicating a potential upside of 28.92%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
Bausch + Lomb
0 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)

Warby Parker has higher earnings, but lower revenue than Bausch + Lomb. Warby Parker is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$669.77M2.40-$63.20M-$0.47-34.49
Bausch + Lomb$4.15B1.28-$260M-$0.96-15.72

Bausch + Lomb has a net margin of -7.81% compared to Warby Parker's net margin of -7.89%. Bausch + Lomb's return on equity of 3.60% beat Warby Parker's return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker-7.89% -13.19% -6.99%
Bausch + Lomb -7.81%3.60%1.94%

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 26.6% of Warby Parker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Warby Parker has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

In the previous week, Warby Parker had 15 more articles in the media than Bausch + Lomb. MarketBeat recorded 18 mentions for Warby Parker and 3 mentions for Bausch + Lomb. Warby Parker's average media sentiment score of 0.68 beat Bausch + Lomb's score of 0.28 indicating that Warby Parker is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
10 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Bausch + Lomb
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)


Bausch + Lomb beats Warby Parker on 9 of the 17 factors compared between the two stocks.

Get Warby Parker News Delivered to You Automatically

Sign up to receive the latest news and ratings for WRBY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WRBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WRBY vs. The Competition

MetricWarby ParkerOphthalmic goods IndustryMedical SectorNYSE Exchange
Market Cap$1.61B$11.39B$5.18B$17.57B
Dividend YieldN/A1.63%2.79%3.58%
P/E Ratio-34.4936.46121.3522.23
Price / Sales2.406.012,238.2515.21
Price / CashN/A20.7534.5219.58
Price / Book5.263.894.864.80
Net Income-$63.20M$224.33M$110.71M$978.08M
7 Day Performance-2.53%-2.97%-0.44%0.65%
1 Month Performance3.18%10.29%-2.10%-4.26%
1 Year Performance36.68%0.09%-0.16%6.27%

Warby Parker Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Bausch + Lomb
2.6312 of 5 stars
-23.3%$5.26B$4.15B-15.5813,300Short Interest ↑
1.8857 of 5 stars
+125.3%$2.13B$89.08M-45.65374Positive News
STAAR Surgical
4.6441 of 5 stars
-21.7%$1.90B$322.42M124.901,115Analyst Upgrade
News Coverage
National Vision
3.8397 of 5 stars
-49.5%$1.13B$2.13B-15.6113,998Positive News
Innovative Eyewear
1.3613 of 5 stars
-80.4%$11.84M$1.15M0.0011Short Interest ↑
News Coverage
Gap Up
1.7431 of 5 stars
+12.1%$44.69B$9.46B42.9525,000Analyst Revision
Cooper Companies
2.7205 of 5 stars
+1.7%$18.67B$3.59B55.0815,000Positive News
Blueprint Medicines
0.5211 of 5 stars
3.7332 of 5 stars
-16.9%$6.59B$2.05B84.475,200Short Interest ↑
Revolution Medicines
3.6037 of 5 stars
+53.6%$6.44B$11.58M-10.41378Positive News

Related Companies and Tools

This page (NYSE:WRBY) was last updated on 6/16/2024 by Staff

From Our Partners